The mission of Oxygen Biotherapeutics is to research, develop and market oxygen related products based on our perfluorocarbon technology.
Currently, we have one product candidate, Oxycyte PFC emulsion, in Phase IIb clinical trials in Switzerland and Israel for use in treating traumatic brain injury (TBI).
Products & Indications
Traumatic Brain Injury
Oxygen Biotherapeutics Selects Duke Clinical Research Institute to Conduct Phase 3 Trial of Levosimendan
Phase 3 trials anticipated to begin in Q3 2014 and to be conducted at 50 major cardiac surgery centers in North America
MORRISVILLE, N.C.--(BUSINESS WIRE)--Dec. 11, 2013-- Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT), a pharmaceutical company focused on developing drugs for the acute care market, today announced that it has selected Duke University’s Duke Clinical Research Institute, (DCRI) to conduct the Phase 3 trial of the Company’s newly acquired compound, levosimendan. DCRI is the world’s largest academic clinical research organization, with substantial experience in conducting cardiac surgery trials. The DCRI will serve as the coordinating center and Drs. John H. Alexander and Rajendra Mehta as lead investigators for the Phase 3 trial. more..
- To participate in our annual share holder meeting, call 877-836-0197 OR you can participate via webcast
- News and Events
- Press Releases
About Oxygen Biotherapeutics
Oxygen Biotherapeutics is the tissue oxygenation company
Oxygen is essential to life. When that supply is shut off the results can range from minor to devastating. At Oxygen Biotherapeutics, our goal is to help the human body maintain a sufficient oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is interrupted or diminished.
Currently, we are developing medical products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Our most advanced product, Oxycyte PFC, is in Phase IIb clinical trials in Switzerland and Israel for traumatic brain injury. Oxycyte PFC is an intravenously delivered perfluorocarbon-based drug that we believe has therapeutic benefits for acute ischemic conditions. The first cohort of the Phase IIb trail is complete. Trials resumed in May 2013 in Israel with planned expansions in other countries. more..
Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced the closing of its acquisition of certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), a significant unmet medical need. Pursuant to the previously announced Purchase Agreement, Oxygen Biotherapeutics acquired the exclusive rights to develop and commercialize levosimendan in North America, and will welcome three key Phyxius Pharma executives into its management team. more...